111 related articles for article (PubMed ID: 8947584)
1. Heterogenous effects of bryostatin on human myeloid leukemia clonogenicity: dose and time scheduling dependency.
van der Hem KG; Schuurhuis GJ; Dräger AM; Odding JH; Huijgens PC
Leuk Res; 1996 Sep; 20(9):743-50. PubMed ID: 8947584
[TBL] [Abstract][Full Text] [Related]
2. Role of TNF alpha in bryostatin-induced inhibition of human hematopoiesis.
Dräger AM; van der Hem KG; Zevenbergen A; Odding JH; Huijgens PC; Schuurhuis GJ
Leukemia; 1999 Jan; 13(1):62-9. PubMed ID: 10049062
[TBL] [Abstract][Full Text] [Related]
3. Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency.
van der Hem KG; Dräger AM; Odding JH; Huijgens PC
Leuk Res; 1995 Sep; 19(9):651-7. PubMed ID: 7564476
[TBL] [Abstract][Full Text] [Related]
4. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.
Steube KG; Drexler HG
Leuk Lymphoma; 1993 Jan; 9(1-2):141-8. PubMed ID: 8477194
[TBL] [Abstract][Full Text] [Related]
5. Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells.
van der Hem KG; Dräger AM; Odding JH; Langenhuijsen MM; Huijgens PC
Leuk Res; 1995 Jan; 19(1):7-13. PubMed ID: 7837820
[TBL] [Abstract][Full Text] [Related]
6. Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.
Grant S; Pettit GR; Howe C; McCrady C
Leukemia; 1991 May; 5(5):392-8. PubMed ID: 2033960
[TBL] [Abstract][Full Text] [Related]
7. Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells.
Grant S; Traylor R; Bhalla K; McCrady C; Pettit GR
Leukemia; 1992 May; 6(5):432-9. PubMed ID: 1593908
[TBL] [Abstract][Full Text] [Related]
8. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.
Jones RJ; Sharkis SJ; Miller CB; Rowinsky EK; Burke PJ; May WS
Blood; 1990 Mar; 75(6):1319-23. PubMed ID: 2310830
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin 1 acts synergistically with interleukin-1 alpha to induce secretion of G-CSF and other cytokines from marrow stromal cells.
Lilly M; Vo K; Le T; Takahashi G
Exp Hematol; 1996 Apr; 24(5):613-21. PubMed ID: 8605966
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
[TBL] [Abstract][Full Text] [Related]
11. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM
Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346
[TBL] [Abstract][Full Text] [Related]
12. Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh.
al-Katib A; Mohammad RM; Khan K; Dan ME; Pettit GR; Sensenbrenner LL
J Immunother Emphasis Tumor Immunol; 1993 Jul; 14(1):33-42. PubMed ID: 8399068
[TBL] [Abstract][Full Text] [Related]
13. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.
Jarvis WD; Povirk LF; Turner AJ; Traylor RS; Gewirtz DA; Pettit GR; Grant S
Biochem Pharmacol; 1994 Mar; 47(5):839-52. PubMed ID: 8135859
[TBL] [Abstract][Full Text] [Related]
14. Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors.
Esa AH; Boto WO; Adler WH; May WS; Hess AD
Int J Immunopharmacol; 1990; 12(5):481-90. PubMed ID: 2210911
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C.
Isakov N; Galron D; Mustelin T; Pettit GR; Altman A
J Immunol; 1993 Feb; 150(4):1195-204. PubMed ID: 8432975
[TBL] [Abstract][Full Text] [Related]
17. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin.
Lilly M; Tompkins C; Brown C; Pettit G; Kraft A
Cancer Res; 1990 Sep; 50(17):5520-5. PubMed ID: 2386956
[TBL] [Abstract][Full Text] [Related]
18. The effect of bryostatin on protein kinase C-regulated functions in human T lymphocytes and epidermal keratinocytes.
Galron D; Tamir A; Gelkop S; Grossman N; Isakov N
Immunol Lett; 1993 Dec; 39(1):17-22. PubMed ID: 8144186
[TBL] [Abstract][Full Text] [Related]
19. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1.
Roddie PH; Horton Y; Turner ML
Leukemia; 2002 Jan; 16(1):84-93. PubMed ID: 11840267
[TBL] [Abstract][Full Text] [Related]
20. Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines.
Steube KG; Grunicke D; Drexler HG
Invest New Drugs; 1994; 12(1):15-23. PubMed ID: 7960600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
